Literature DB >> 32436368

MicroRNA-155 deficiency attenuates inflammation and oxidative stress in experimental autoimmune prostatitis in a TLR4-dependent manner.

Xian Fu1, Hua-Dong He1, Chang-Jiu Li2, Ning Li1, Shu-Yuan Jiang2, Hong-Wei Ge1, Rui Wang2, Xu-Liang Wang1.   

Abstract

To explore the mechanism of microRNA-155 (miR-155) deficiency, protecting against experimental autoimmune prostatitis (EAP) in a toll-like receptor 4 (TLR4)-dependent manner. After wild-type (WT) and miR-155-/- mice were injected with complete Freund's adjuvant and prostate antigen to establish EAP model, half were randomly selected for injection with lipopolysaccharide (LPS, a TLR4 ligand). The following experiments were then performed: von Frey filaments, hematoxylin-eosin (HE) staining, real time quantitative polymerase chain reaction (qRT-PCR), Western blotting, and enzyme-linked immunosorbent assay (ELISA). And the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and the level of Malondialdehyde (MDA) were detected by corresponding kits.miR-155-/- mice with prostatitis exhibited the attenuated pelvic tactile allodynia/hyperalgesia and the suppressed TLR4/nuclear factor-kappa B (NF-κB) pathway as compared with the WT mice with prostatitis. In addition, LPS enhanced the upregulation of miR-155 and the activation of the TLR4/NF-κB pathway in the prostatic tissues of WT mice with EAP. Furthermore, prostatitis mice had aggravated inflammation scores accompanying the increased interleukin (IL)-1β, tumor necrosis factor-α, IL-6, interferon-γ, IL-12, and MDA in prostatic tissues with the decreased IL-10, SOD and GSH-Px, and the unaltered IL-4. Compared with the mice from the WT + EAP group and the miR-155-/- + EAP + LPS group, mice from the miR-155-/- + EAP group had decreased inflammation and oxidative stress. miR-155 deficiency ameliorated pelvic tactile allodynia/hyperalgesia in EAP mice and improved inflammation and oxidative stress in prostatic tissues in a TLR4-dependent manner involving NF-κB activation, thereby exerting a therapeutic effect in chronic prostatitis treatment.
© 2020 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.

Entities:  

Keywords:  MicroRNA-155; NF-κB; TLR4; autoimmune chronic prostatitis

Mesh:

Substances:

Year:  2020        PMID: 32436368     DOI: 10.1002/kjm2.12229

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  5 in total

1.  Effect of thermophilic bacterium HB27 manganese superoxide dismutase in a rat model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

Authors:  Nai-Wen Chen; Jing Jin; Hong Xu; Xue-Cheng Wei; Ling-Feng Wu; Wen-Hua Xie; Yu-Xiang Cheng; Yi He; Jin-Lai Gao
Journal:  Asian J Androl       Date:  2022 May-Jun       Impact factor: 3.054

2.  Anthocyanin Protects Cardiac Function and Cardiac Fibroblasts From High-Glucose Induced Inflammation and Myocardial Fibrosis by Inhibiting IL-17.

Authors:  Er Yue; Yahan Yu; Xinyao Wang; Bing Liu; Yunlong Bai; Baofeng Yang
Journal:  Front Pharmacol       Date:  2021-02-02       Impact factor: 5.810

3.  Inhibition of miR-155 Attenuates CD14+ Monocyte-Mediated Inflammatory Response and Oxidative Stress in Psoriasis Through TLR4/MyD88/NF-κB Signaling Pathway.

Authors:  Jiajie Li; Yanmin Liu; Yue Cao; Juanjuan Wang; Xingcheng Zhao; Juanjuan Jiao; Junqin Li; Kaiming Zhang; Guohua Yin
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-02-09

4.  Prostatic fluid exosome-mediated microRNA-155 promotes the pathogenesis of type IIIA chronic prostatitis.

Authors:  Baixiong Zhao; Jun Zheng; Yang Qiao; Yongquan Wang; Yang Luo; Dinglin Zhang; Qiyan Cai; Yang Xu; Zhansong Zhou; Wenhao Shen
Journal:  Transl Androl Urol       Date:  2021-05

Review 5.  TLR4 signaling in the development of colitis-associated cancer and its possible interplay with microRNA-155.

Authors:  Jie Guo; Mengfan Liao; Jun Wang
Journal:  Cell Commun Signal       Date:  2021-09-03       Impact factor: 5.712

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.